Crescent Biopharma, Inc.

Healthcare · Biotechnology · United States

Last price 13.39 USD (Oct 30, 2026, 2:56 PM EDT) · Market cap 573.11M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head...